. 2023 Mar 11;9:38. doi: 10.1038/s41531-023-00476-2

Table 6.

Baseline demographic, clinical and inflammatory data from people with Parkinson´s disease with GBA mutation stratified by cognitive status.

	PD_GBA no CI during study	PD_GBA new CI during study	PD_GBA CI at baseline	p value PD groups
	n = 44	n = 15	n = 39
GBA severity, % (n)	Risk 48 (21) Mild 27 (12) Severe 25 (11)	Risk 40 (6) Mild 20 (3) Severe 40 (6)	Risk 40 (21) Mild 13 (5) Severe 33 (13)
Male, % (n)	71 (31)	53 (8)	69 (27)	0.450
Age, years	58 ± 10	66 ± 6	63 ± 9	<0.001
Age at onset, years	51 ± 11	60 ± 8	57 ± 8	0.003
Disease duration, years	7 ± 5	6 ± 3	10 ± 6	0.014
H&Y	2.0 ± 0.5	2.0 ± 0.5	2.4 ± 0.8	0.659^a
UPDRS-III	25 ± 10	28 ± 14	29 ± 13	0.824^a
MoCA	28 ± 2	27 ± 1	20 ± 4	<0.001^a
LEDD	598 ± 498	826 ± 456	526 ± 335	0.021^a
Amyloidβ_1-42 [pg/ml]	709 ± 258	694 ± 221	710 ± 254	0.851^a
total-Tau [pg/ml]	230 ± 89	219 ± 79	272 ± 183	0.381^a
phospho181-Tau [pg/ml]	40 ± 15	39 ± 14	40 ± 18	0.274^a
NFL [pg/ml]	815 ± 675	775 ± 321	1059 ± 593	0.616^a
α-synuclein [pg/ml]	538 ± 236	609 ± 347	529 ± 236	0.183^a
Eotaxin-1	58.0 ± 6.8	58.0 ± 5.9	57.4 ± 8.6	0.981^a
Factor-VII	499 ± 250	462 ± 150	456 ± 163	0.771^a
ICAM-1	482 ± 162	465 ± 156	541 ± 208	0.752^a
Interleukin-1ra	20.7 ± 10.6	20.2 ± 10.4	20.0 ± 9.9	0.977^a
Interleukin-2	10.7 ± 6.4	11.4 ± 7.5	11.3 ± 6.5	0.985^a
Interleukin-4	9.43 ± 5.50	7.08 ± 2.88	9.08 ± 5.09	0.613^a
Interleukin-6	0.99 ± 0.34	0.98 ± 0.28	1.04 ± 0.46	0.849^a
Interleukin-7	3.85 ± 2.04	4.25 ± 2.78 n = 7	5.13 ± 3.43	0.087^a
Interleukin-8	38.7 ± 12.4	36.2 ± 6.9	43.7 ± 12.3	0.368^a
Interleukin-12p40	0.11 ± 0.05	0.09 ± 0.02	0.14 ± 0.07	0.127^a
Interleukin-18	8.23 ± 4.9	8.93 ± 4.43	9.78 ± 4.87	0.485^a
MCP-1	668 ± 230	741 ± 179	750 ± 210	0.887^a
MIP-1 alpha	9.5 ± 3.8	9.3 ± 5.0	10.7 ± 5.6	0.565^a
MIP-1 beta	62.6 ± 17.5	66.9 ± 16.3	68.0 ± 19.5	0.945^a
MMP3	128 ± 53	132 ± 51	150 ± 86	0.963^a
MMP9	6249 ± 2960	6052 ± 2534	6771 ± 3533	0.361^a
SCF	69.6 ± 27.5	76.9 ± 23.7	80.0 ± 29.0	0.909^a
TNF-alpha	2.97 ± 0.74	2.97 ± 0.44 n = 8	3.40 ± 1.19	0.471^a
VEGF	35.0 ± 5.7	36.4 ± 6.0	38.1 ± 5.8	0.525^a

Data were presented as mean and standard deviation.

CI cognitive impairment.

^aANCOVA with age and disease duration as co-variable.